

Daniela Merlotti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3994334/daniela-merlotti-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

2,615
citations

28
h-index

49
g-index

79
ext. papers

2,983
ext. citations

5.2
avg. IF

4.54
L-index

#	Paper	IF	Citations
76	Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes.. <i>Frontiers in Public Health</i> , 2021 , 9, 736665	6	18
75	Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. <i>BMC Infectious Diseases</i> , 2021 , 21, 566	4	28
74	Infection by CagA-Positive Helicobacter pylori Strains and Bone Fragility: A Prospective Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 80-89	6.3	2
73	Energy Metabolism and Ketogenic Diets: What about the Skeletal Health? A Narrative Review and a Prospective Vision for Planning Clinical Trials on this Issue. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
72	Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders. <i>Calcified Tissue International</i> , 2021 , 108, 757-763	3.9	1
71	Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2210-2233	4.5	2
70	Mutation of PFN1 Gene in an Early Onset, Polyostotic Paget-like Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	10
69	Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2020 , 15, 283-298	4.1	9
68	Emerging therapeutic targets for osteoporosis. <i>Expert Opinion on Therapeutic Targets</i> , 2020 , 24, 115-130.	4	8
67	Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu. <i>Endocrine</i> , 2020 , 68, 411-419	4	7
66	Treatment options for glucocorticoid-induced osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 721-732	4	13
65	Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	7
64	Increased Prevalence of Nephrolithiasis and Hyperoxaluria in Paget Disease of Bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
63	Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4441-4448	5.6	14
62	Paget's Disease of Bone. <i>Calcified Tissue International</i> , 2019 , 104, 483-500	3.9	32
61	Vitamin D Status in Paget Disease of Bone and Efficacy-Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D. <i>Calcified Tissue International</i> , 2019 , 105, 412-422	3.9	5
60	Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone. <i>Pain</i> , 2018 , 159, 1664-1673	8	3

59	Paget's disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 485-496	1.1	9
58	Recent advances in models for screening potential osteoporosis drugs. <i>Expert Opinion on Drug Discovery</i> , 2018 , 13, 741-752	6.2	1
57	The Potential Role of miRNAs as New Biomarkers for Osteoporosis. <i>International Journal of Endocrinology</i> , 2018 , 2018, 2342860	2.7	22
56	Treatment needs and current options for postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1141-52	4	52
55	ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. <i>American Journal of Human Genetics</i> , 2016 , 98, 275-86	11	39
54	Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD) : study design, clinical procedures and treatment protocol. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015 , 22, 135-42	2.9	3
53	Appropriate models for novel osteoporosis drug discovery and future perspectives. <i>Expert Opinion on Drug Discovery</i> , 2015 , 10, 1201-16	6.2	18
52	Clinical characteristics and evolution of giant cell tumor occurring in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 257-63	6.3	30
51	Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 992-1000	6.9	26
50	Paget's disease of bone: epidemiology, pathogenesis and pharmacotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 591-603	1.1	2
49	Giant cell tumor occurring in familial Paget's disease of bone: report of clinical characteristics and linkage analysis of a large pedigree. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 341-50	6.3	15
48	Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2338-46	6.3	43
47	Nuove acquisizioni patogenetiche e terapeutiche della malattia ossea di Paget. <i>L'Endocrinologo</i> , 2013 , 14, 120-127	0	
46	Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. <i>Frontiers in Endocrinology</i> , 2013 , 4, 73	5.7	25
45	Endocrine actions of osteocalcin. <i>International Journal of Endocrinology</i> , 2013 , 2013, 846480	2.7	84
44	Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1737-44	5.6	183
43	A nonsynonymous TNFRSF11A variation increases NFB activity and the severity of Paget's disease. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 443-52	6.3	31
42	Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 505-13	5.5	5

41	Aromatase activity and bone loss. <i>Advances in Clinical Chemistry</i> , 2011 , 54, 129-64	5.8	13
40	Aromatase activity and bone loss in men. <i>Journal of Osteoporosis</i> , 2011 , 2011, 230671	2.8	19
39	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. <i>Nature Genetics</i> , 2011 , 43, 685-9	36.3	134
38	The association of body composition and sex hormones with quantitative ultrasound parameters at the calcaneus and phalanges in elderly women. <i>Calcified Tissue International</i> , 2011 , 89, 456-63	3.9	13
37	Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 512-8	6.3	20
36	Lasofexifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. <i>Expert Opinion on Drug Discovery</i> , 2011 , 6, 205-17	6.2	4
35	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofexifene. <i>Clinical Interventions in Aging</i> , 2010 , 5, 19-29	4	34
34	FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. <i>European Journal of Endocrinology</i> , 2010 , 163, 165-72	6.5	76
33	Epidemiological, clinical, and genetic characteristics of Paget's disease of bone in a rural area of Calabria, Southern Italy. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 519-25	5.2	10
32	Mechanisms of impaired bone strength in type 1 and 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010 , 20, 683-90	4.5	79
31	SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 1375-84	6.3	58
30	Lasofexifene: Evidence of its therapeutic value in osteoporosis. <i>Core Evidence</i> , 2010 , 4, 113-29	4.9	8
29	Lasofexifene: a new-generation SERM for the treatment of postmenopausal osteoporosis. <i>Expert Review of Obstetrics and Gynecology</i> , 2009 , 4, 607-617		
28	The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009 , 9, 1052-63	3.2	16
27	Ospemifene use in postmenopausal women. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 839-49	5.9	26
26	Update on the pharmacogenetics of the vitamin D receptor and osteoporosis. <i>Pharmacogenomics</i> , 2009 , 10, 417-33	2.6	18
25	Current options for the treatment of Paget's disease of the bone. <i>Open Access Rheumatology: Research and Reviews</i> , 2009 , 1, 107-120	2.4	10
24	Malattia di Paget 2009 , 243-254		

23	Raloxifene in breast cancer prevention. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 259-70	4.1	25
22	The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. <i>Thyroid</i> , 2008 , 18, 455-60	6.2	64
21	Bazedoxifene for the prevention of postmenopausal osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 1229-42	2.9	23
20	The effects of zoledronic acid on serum lipids in multiple myeloma patients. <i>Calcified Tissue International</i> , 2008 , 82, 258-62	3.9	18
19	Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone. <i>Calcified Tissue International</i> , 2008 , 83, 414-24	3.9	15
18	Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic review. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 537-53	4	22
17	Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 1510-7	6.3	61
16	Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. <i>Bone</i> , 2007 , 40, 457-63	4.7	62
15	Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. <i>Drugs and Aging</i> , 2007 , 24, 361-79	4.7	81
14	Lasofloxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1091-103	5.9	42
13	Paget's disease of bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2006 , 21 Suppl 2, P14-21	6.3	50
12	Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 1828-35	6.3	51
11	Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. <i>American Journal of Epidemiology</i> , 2005 , 161, 307-20	3.8	168
10	Characteristics and familial aggregation of Paget's disease of bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1356-64	6.3	57
9	Prevalence of Paget's disease of bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1845-50	6.3	65
8	Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in men. <i>Osteoporosis International</i> , 2005 , 16, 963-8	5.3	74
7	Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 847-52	4	43
6	A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2803-10	5.6	141

5	Feasibility of quantitative ultrasound measurements on the humerus of newborn infants for the assessment of the skeletal status. <i>Osteoporosis International</i> , 2004 , 15, 541-6	5.3	26
4	Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5327-33	5.6	203
3	Mild brachydactyly type A1 maps to chromosome 2q35-q36 and is caused by a novel IHH mutation in a three generation family. <i>Journal of Medical Genetics</i> , 2003 , 40, 132-5	5.8	21
2	HLA antigens and primary osteoarthritis of the hand. <i>Journal of Rheumatology</i> , 2003 , 30, 1298-304	4.1	8
1	Molecular Genetics of Paget's Disease of Bone		2